The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
“agree ... still filling this years ISA allowance Ruck .... managed last years ok ... did you ?”
Do you remember the Harry Enfield character who kept saying “I am considerably richer than yow”?
busy at the moment, thought i would transfer another £1000 ... buy a few more rather than spend on diesel ..
Inan,
“Bermuda ... NDA ... Non Disclosure agreement ... ? exactly how can i answer you ?“
Are you suggesting the NDA that Scancell are under prevents them from disclosing ANYTHING to the market? Lol
Or are you suggesting that YOU are under an NDA yourself preventing you from answering any questions?
You haven’t disclosed any signs of sense so far!
agree ... still filling this years ISA allowance Ruck .... managed last years ok ... did you ?
every AGM i attended .... first question Funding ........
your question .. is fine
hence you received an answer ... "within guidelines"
not price sensitive
...
Especially as you can’t afford the money for diesel to get there.
Inan,
I have only ever asked one question at an AGM..
Q. Will you issue an RNS when the first patient has been dosed?
A. Yes.
The Q&A in total took 17 seconds and I believe was useful to many investors.
I’m not sure why you feel you need to be the AGM question prefect?
Bermuda ... NDA ... Non Disclosure agreement ... ? exactly how can i answer you ?
sorry to duplicate not sure what happened
Ruck why are you getting so excited ? .. i am not scancell
""" I sincerely hope we get some communication BEFORE the next AGM. if not, it’s the responsibility of the BOD to decide what answers they can give, not the responsibility of investors to decide what they can ASK."""
you waste "Valuable " question Time by asking questions that cannot be answered at AGM ... makes no difference to the BOD as they probably know the answers ... so they can spend 10 mins in Political maneuvering evading. "its Your time you have wasted"
Ruck why are you getting so excited ? .. i am not scancell
we have not had updates .... apart from when a collaboration gets extended ie Karolina .. so we know that they have something interest ... but what ...
then Karolinska also holds a certain IP of value ... do you see my point .. ?
Inan,
Forget IP, NDA etc. Think about the situation with the SCIB1 (our most advanced platform) which officially is “in the clinic”.
Has the trial been put on hold
Or
Is it proceeding as normal
Or
Is it Proceeding but slower than expected.
Thats not too complicated for a comment from the company surely?
Sorry Inanaco, are you suggesting that NDAs are preventing Scancell from issuing an update?
Inanaco,
I was thinking of the clinical trial protocol. I assume they'd keep the SCIB1 dosing schedule the same but the dosing regime for Keytruda is currently once every 3 weeks, so assume they'd need to apply to FDA/MHRA for a protocol amendment. Not a big issue but probably something they could do without.
Anyway, most likely won't arise and Nottingham will simply resume recruitment and at some stage Scancell will tell us about the new UK study centres and hopefully US ones too.
I agree, an individual PI asking the CSO what’s going on and reporting back to a BB is not the way to do it.
What we need is proper communication from the CEO using the correct channels so all investors have the same information at the same time.
We have precious little information since the 19th August 2019 announcement that UK trials were to start “immediately”.
I sincerely hope we get some communication BEFORE the next AGM. if not, it’s the responsibility of the BOD to decide what answers they can give, not the responsibility of investors to decide what they can ASK.
another angle that folks have not considered on the Collaborations ..
the other parties IP is usually involved ... making issuing of RNS quite complex .. and why NDA from both sides have equal importance
No when i have tried in the past to squeeze info .. the door gets shut ie no reply .. if i ask a specific question on the science that is in the public domain ... for instance the patent .. then it gets answered
this is why i say the questions at the AGM directed at the BOD have to be done in such a way as to evade Price sensitivity .. if you don't do that then the brush off appears from the BOD ... which makes it worse, because the average investor wants to know, but they cannot tell you .. unless its Via RNS
Inan,
Worth a shout out to our Lindy on this?
Just a thought
ATB
i am not sure how the pre-clinical work of SCIB1 say giving once per month (keytruda) would change if given every 2 ...
and Scib2 for that matter that is quite a Jolt to the immune system ...
Interesting, I know in the US they've been trying to find all sorts of ways to keep clinical trials going - including visiting the patient at home to administer the drugs. Of course that's not an option for the SCIB1 trial. From Scancell's point of view, I hope they don't like this new dosing regime so much that they stick with it or are slow to change back, although it may be much better for patients, especially in the US.
As for holding up the SCIB1 trial, I really don't think that's the case - the trial had been up and running for 6 months prior to lockdown and hadn't dosed a single patient - think it's much more likely that it was simply put on hold. I'm happy to explain my reasoning if you like. Having said that, this is a perfect example of why it would have been good if Scancell had issued an update on the impact of COVID-19, we shouldn't have to guess about something so fundamentally important to Scancell's core business.
https://www.pharmaceutical-technology.com/comment/keytruda-cancer-drug/
Guidelines for melanoma ... covid
this bit is of huge relevance
For patients on PD-1 blockade, prefer double dosing with double interval to reduce visits: pembrolizumab 400 mg q6w and nivolumab 480 mg q4w with one inter-cure visit in telemedicine with blood exams performed in a laboratory close to the patient if a suitable COVID-19-protected facility is available, otherwise at the centre under current precautions
might explain why they have not started yet
https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/melanoma-in-the-covid-19-era